145 related articles for article (PubMed ID: 12600417)
1. The MTS assay as an indicator of chemosensitivity/resistance in malignant gynaecological tumours.
O'Toole SA; Sheppard BL; McGuinness EP; Gleeson NC; Yoneda M; Bonnar J
Cancer Detect Prev; 2003; 27(1):47-54. PubMed ID: 12600417
[TBL] [Abstract][Full Text] [Related]
2. Serous papillary adenocarcinomas of the ovary display heterogeneity in their response to chemotherapy.
O'Toole SA; Sheppard BL; McGuinness E; Gleeson NC; Bonnar J
Int J Gynecol Cancer; 2001; 11(5):365-71. PubMed ID: 11737467
[TBL] [Abstract][Full Text] [Related]
3. [Predictive value of in vitro MTT assay chemosensitivity test of cytotoxic drug activity in cervical cancer].
Xiao Y; Li JD; Shi HL; Liu JH; Feng YL; Li MD
Ai Zheng; 2007 Apr; 26(4):386-9. PubMed ID: 17430657
[TBL] [Abstract][Full Text] [Related]
4. Chemosensitivity testing of a novel platinum analog, nedaplatin (254-S), in human gynecological carcinomas: a comparison with cisplatin.
Koshiyama M; Kinezaki M; Uchida T; Sumitomo M
Anticancer Res; 2005; 25(6C):4499-502. PubMed ID: 16334133
[TBL] [Abstract][Full Text] [Related]
5. Prediction of chemotherapeutic response in unresectable non-small-cell lung cancer (NSCLC) patients by 3-(4,5-dimethylthiazol-2-yl)-5-(3-carboxymethoxyphenyl)-2- (4-sulfophenyl)-2H-tetrazolium (MTS) assay.
Chen J; Cheng GH; Chen LP; Pang TY; Wang XL
Asian Pac J Cancer Prev; 2013; 14(5):3057-62. PubMed ID: 23803079
[TBL] [Abstract][Full Text] [Related]
6. Potential use of the adenosine triphosphate cell viability assay in endometrial cancer.
Tam KF; Ng TY; Tsang PC; Li CF; Ngan HY
J Soc Gynecol Investig; 2006 Oct; 13(7):518-22. PubMed ID: 16979354
[TBL] [Abstract][Full Text] [Related]
7. [-Chemosensitivity testing in gynecologic oncology. Experiences with an ATP bioluminescence assay-].
Kurbacher CM; Mallmann P; Kurbacher JA; Hübner H; Krebs D
Geburtshilfe Frauenheilkd; 1996 Feb; 56(2):70-8. PubMed ID: 8647362
[TBL] [Abstract][Full Text] [Related]
8. Evaluation of chemosensitivity testing with highly purified tumor cells in 435 patients with gastric carcinoma using an MTT assay.
Noguchi K; Iwahashi M; Tani M; Nakamura M; Nakamori M; Nakatani Y; Ueda K; Ishida K; Naka T; Ojima T; Hotta T; Mizobata S; Yamaue H
Anticancer Res; 2005; 25(2A):931-7. PubMed ID: 15868930
[TBL] [Abstract][Full Text] [Related]
9. Expression of multidrug resistance (MDR) proteins and in vitro drug resistance in acute leukemias.
Fazlina N; Maha A; Jamal R; Zarina AL; Cheong SK; Hamidah H; Ainoon O; Zulkifli SZ; Hamidah NH
Hematology; 2007 Feb; 12(1):33-7. PubMed ID: 17364990
[TBL] [Abstract][Full Text] [Related]
10. [Relationship between the expression of P-glycoprotein, glutathione S-transferase-pi and thymidylate synthase proteins and adenosine triphosphate tumor chemosensitivity assay in cervical cancer].
Gao GL; Wan HY; Zou XS; Chen WX; Chen YQ; Huang XZ
Zhonghua Fu Chan Ke Za Zhi; 2007 Mar; 42(3):201-5. PubMed ID: 17537309
[TBL] [Abstract][Full Text] [Related]
11. Chemosensitivity testing of clinical gastrointestinal cancers using histoculture and the MTT end-point.
Furukawa T; Kubota T; Watanabe M; Kase S; Takahara T; Yamaguchi H; Takeuchi T; Teramoto T; Ishibiki K; Kitajima M
Anticancer Res; 1992; 12(5):1377-82. PubMed ID: 1444194
[TBL] [Abstract][Full Text] [Related]
12. Tumor heterogeneity and in vitro chemosensitivity testing in ovarian cancer.
Sevin BU; Perras JP
Am J Obstet Gynecol; 1997 Apr; 176(4):759-66; discussion 766-8. PubMed ID: 9125599
[TBL] [Abstract][Full Text] [Related]
13. High-throughput screening platform for anticancer therapeutic drug cytotoxicity.
Sekhon BK; Roubin RH; Tan A; Chan WK; Sze DM
Assay Drug Dev Technol; 2008 Oct; 6(5):711-21. PubMed ID: 19035851
[TBL] [Abstract][Full Text] [Related]
14. Assessment of in vitro drug resistance of human breast cancer cells subcultured from biopsy specimens.
Krasna L; Netikova I; Chaloupkova A; Taislova E; Zimovjanova M; Vesely P; Danes J; Petruzelka L; Matouskova E
Anticancer Res; 2003; 23(3B):2593-9. PubMed ID: 12894546
[TBL] [Abstract][Full Text] [Related]
15. [Predicting clinical chemo-sensitivity of primary ovarian cancer using adenosine triphosphate-tumor chemosensitivity assay combined with detection of drug resistance genes].
Zhao D; Zhang W; Li XG; Wang XB; Zhang LF; Li M; Li YF; Tian HM; Song PP; Liu J; Chang QY; Wu LY
Zhonghua Fu Chan Ke Za Zhi; 2011 Mar; 46(3):193-8. PubMed ID: 21575453
[TBL] [Abstract][Full Text] [Related]
16. Short-term in vitro chemosensitivity testing of tumours of the ovary, cervix and uterus. Measurement of DNA metabolism by 3H thymidine incorporation.
Khoo SK; Hurst T; Webb MJ; Mackay EV
Aust N Z J Obstet Gynaecol; 1986 Nov; 26(4):288-94. PubMed ID: 3469997
[TBL] [Abstract][Full Text] [Related]
17. Association between in vitro platinum resistance in the EDR assay and clinical outcomes for ovarian cancer patients.
Holloway RW; Mehta RS; Finkler NJ; Li KT; McLaren CE; Parker RJ; Fruehauf JP
Gynecol Oncol; 2002 Oct; 87(1):8-16. PubMed ID: 12468336
[TBL] [Abstract][Full Text] [Related]
18. Correlation of drug response with the ATP tumorchemosensitivity assay in primary FIGO stage III ovarian cancer.
Konecny G; Crohns C; Pegram M; Felber M; Lude S; Kurbacher C; Cree IA; Hepp H; Untch M
Gynecol Oncol; 2000 May; 77(2):258-63. PubMed ID: 10785475
[TBL] [Abstract][Full Text] [Related]
19. [Correlation between ATP bioluminescence tumor chemosensitivity assay and clinical response in ovarian cancer].
Tian HM; Shi XY; Fu J; Chao DY; Zhang K; Wu LY; Wang JW; Zhang W
Zhonghua Zhong Liu Za Zhi; 2005 May; 27(5):296-8. PubMed ID: 15996325
[TBL] [Abstract][Full Text] [Related]
20. Evaluation of optimal drug concentration in histoculture drug response assay in association with clinical efficacy for head and neck cancer.
Hasegawa Y; Goto M; Hanai N; Ijichi K; Adachi M; Terada A; Hyodo I; Ogawa T; Furukawa T
Oral Oncol; 2007 Sep; 43(8):749-56. PubMed ID: 17112769
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
